PT  - JOURNAL ARTICLE
AU  - Miyakawa, Kei
AU  - Funabashi, Rikako
AU  - Yamaoka, Yutaro
AU  - Jeremiah, Sundararaj Stanleyraj
AU  - Katada, Junichi
AU  - Wada, Atsuhiko
AU  - Takei, Toshiki
AU  - Shimizu, Kohei
AU  - Ozawa, Hiroki
AU  - Kawakami, Chiharu
AU  - Usuku, Shuzo
AU  - Tanaka, Nobuko
AU  - Yamazaki, Etsuko
AU  - Shimizu, Hideaki
AU  - Okabe, Nobuhiko
AU  - Hasegawa, Hideki
AU  - Ryo, Akihide
TI  - SARS-CoV-2 antigen rapid diagnostic test enhanced with silver amplification technology
AID  - 10.1101/2021.01.27.21250659
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.27.21250659
4099  - http://medrxiv.org/content/early/2021/01/31/2021.01.27.21250659.short
4100  - http://medrxiv.org/content/early/2021/01/31/2021.01.27.21250659.full
AB  - Rapid diagnosis of COVID-19 is essential for instituting measures to prevent viral spread. SARS-CoV-2 antigen rapid diagnostic test (Ag-RDT) based on lateral flow immunochromatography assay (LFIA) principle can visually indicate the presence of SARS-CoV-2 antigens as a band. Ag-RDT is clinically promising as a point-of-care testing because it can give results in a short time without the need for special equipment. Although various antigen capture LFIAs are now available for rapid diagnosis for SARS-CoV-2 infection, they face the problems of low sensitivity. We have previously developed highly specific monoclonal antibodies (mAb) against SARS-CoV-2 nucleocapsid protein (NP) and in this study, we have employed these mAbs to develop a new LFIA that can detect SARS-CoV-2 NP in nasopharyngeal swab samples with higher sensitivity by combining them with silver amplification technology. We also compared the performance of our Ag-RDT against the commercially available Ag-RDTs using clinical samples to find that our newly developed LFIA performed best among tested, highlighting the superiority of silver amplification technology.Competing Interest StatementYY is an employee of Kanto Chemical Co., Inc.; JK, AW, and TT are current employee of FUJIFILM Corporation.; Remaining authors declare that they have no competing interests.Funding StatementThis work was supported in part by Japan Agency for Medical Research and Development (AMED, Grant numbers JP19fk0108110 and JP20he0522001), and by Health Labour Sciences research grant from The Ministry of Health Labour and Welfare (Grant number 19HA1003) to AR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the IRB of Yokohama City University (B200800106).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are available from the authors on request.